[The effect of norkolut on immune system status in patients with dyshormonal myocardial dystrophy and hyperplastic processes of the uterus].
Use of norkolut in 34 patients with dyshormonal myocardiodystrophy per 10 mg from the 16-th through 25-th days of the menstrual cycle for 6 months favoured improvement of clinical, ECG-data, normalization of values of the immune system. Three months after discontinuation of norkolut restoration occurred of T gamma, A-RFC at the I phase of menstrual cycle while the content of B-lymphocytes remains reduced. At the II phase of the menstrual cycle one observed a reduction of the absolute content of T gamma-cells, A-RFC.
Khait
O V
OV
Iakimenko-Vasiutina
E A
EA
D000328:Adult; D009202:Cardiomyopathies / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D004714:Endometrial Hyperplasia / Q000150:complications / Q000276:immunology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use*
D009640:Norethindrone
Vliianie norkoluta na sostoianie immunnoĭ sistemy u bol'nykh s disgormonal'nĭ miokardiodistrofieĭ i giperplasticheskimi protsessami v matke.